» Articles » PMID: 21702042

MiR-34a Chemosensitizes Bladder Cancer Cells to Cisplatin Treatment Regardless of P53-Rb Pathway Status

Overview
Journal Int J Cancer
Specialty Oncology
Date 2011 Jun 25
PMID 21702042
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

MiR-34a is a downstream effector of p53 that has been shown to target several molecules associated with cell cycle and cell survival pathways. As alterations in these pathways are frequent in muscle invasive transitional cell carcinoma of the bladder (MI-TCC), for example mutation or loss of p53 and Rb, the goal of this study was to determine whether manipulation of miR-34a expression levels could abrogate the effect of these alterations and sensitize bladder cancer cells to chemotherapy. We demonstrate that transfection of T24, TCCSUP and 5637 with pre-miR-34a followed by cisplatin treatment results in a dramatic reduction in clonogenic potential and induction of senescence compared to treatment with cisplatin alone. Molecular analyses identified Cdk6 and sirtuin (SIRT)-1 as being targeted by miR-34a in MI-TCC cells, however, inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization. Analysis of 27 preneoadjuvant chemotherapy patient samples revealed many of the patients who subsequently did not respond to treatment (based on surgical resection postchemotherapy and 5-year survival data) express lower levels of miR-34a, however, a statistically significant difference between the responder and nonresponder groups was not observed (p = 0.1174). Analysis of eight sets of pre- and postneoadjuvant chemotherapy patient samples determined miR-34a expression increased postchemotherapy in only two of the eight patients. The combined data indicate that elevation of miR-34a expression levels before chemotherapy would be of benefit to MI-TCC patients, particularly in a setting of low miR-34a expression.

Citing Articles

Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review.

Dimitrov G, Mangaldzhiev R, Slavov C, Popov E Cancers (Basel). 2024; 16(17).

PMID: 39272913 PMC: 11394076. DOI: 10.3390/cancers16173056.


Non-coding RNA and reprogrammed mitochondrial metabolism in genitourinary cancer.

Thirunavukkarasu S, Banerjee S, Tantray I, Ojha R Front Genet. 2024; 15:1364389.

PMID: 38544804 PMC: 10965626. DOI: 10.3389/fgene.2024.1364389.


Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.

Hashem M, Khosroshahi E, Aliahmady M, Ghanei M, Rezaie Y, Jafari Y Noncoding RNA Res. 2024; 9(2):560-582.

PMID: 38515791 PMC: 10955558. DOI: 10.1016/j.ncrna.2024.01.009.


The Roles of miRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.

Das S, Hayden J, Sullivan T, Rieger-Christ K Int J Mol Sci. 2023; 24(2).

PMID: 36674480 PMC: 9864802. DOI: 10.3390/ijms24020964.


A miR-34a-guided, tRNA-derived, piR_019752-like fragment (tRiMetF31) suppresses migration and angiogenesis of breast cancer cells via targeting PFKFB3.

Wang B, Li D, Ilnytskyy Y, Kovalchuk I, Kovalchuk O Cell Death Discov. 2022; 8(1):355.

PMID: 35961977 PMC: 9374763. DOI: 10.1038/s41420-022-01054-w.


References
1.
Herr H, Dotan Z, Donat S, Bajorin D . Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177(2):437-43. DOI: 10.1016/j.juro.2006.09.027. View

2.
Prabhudesai S, Rekhraj S, Roberts G, Darzi A, Ziprin P . Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol. 2007; 96(1):77-88. DOI: 10.1002/jso.20785. View

3.
Yu D, Hsieh D, Chang S . Detection of chromosomal alterations in bladder cancer by comparative genomic hybridization. BJU Int. 2001; 87(9):889-93. DOI: 10.1046/j.1464-410x.2001.02175.x. View

4.
Shariat S, Tokunaga H, Zhou J, Kim J, Ayala G, Benedict W . p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004; 22(6):1014-24. DOI: 10.1200/JCO.2004.03.118. View

5.
Jay C, Nemunaitis J, Chen P, Fulgham P, Tong A . miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007; 26(5):293-300. DOI: 10.1089/dna.2006.0554. View